Daclatasvir Dihydrochloride | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Daclatasvir Dihydrochloride
US Patents

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.

Contact Supplier

Evonik

Contact Supplier

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

xyz-pharma-m-2025-02-24

Contact Supplier

Daclatasvir Dihydrochloride

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

26 API Suppliers, 5 USDMF, 5 EU WC, 4 NDC API, 21 Listed Suppliers, $ API Reference Price

26 API Suppliers
5 USDMF
5 EU WC
4 NDC API
21 Listed Suppliers
$ API Reference Price

INTERMEDIATES

7 Intermediate Suppliers

7 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

14 FDF Dossiers, 3 FDA Orange Book, 6 Europe, 5 Listed Dossiers

14 FDF Dossiers
3 FDA Orange Book
6 Europe
5 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 30MG BASE, TABLET;ORAL - EQ 60MG BASE, TABLET;ORAL - EQ 90MG BASE

TABLET;ORAL - EQ 30MG BASE
TABLET;ORAL - EQ 60MG BASE
TABLET;ORAL - EQ 90MG BASE

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 5 DKSH, 2 Faran Shimi Pharmaceutical, 3 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Clariant, 10 Corel Pharma Chem, 4 DFE Pharma, 6 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 1 Ingredion Pharma Solutions, 21 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 9 Microlex e.U, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 2 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 10 Roquette, 6 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 9 Sigachi Industries, 2 The Dow Chemical Company, 3 Vasa Pharmachem

1 SPI Pharma
5 DKSH
2 Faran Shimi Pharmaceutical
3 Gangwal Healthcare
1 Nanjing Well Pharmaceutical
1 ACG Worldwide
6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
1 Clariant
10 Corel Pharma Chem
4 DFE Pharma
6 Gangwal Chemicals
5 Ideal Cures Pvt Ltd
1 Ingredion Pharma Solutions
21 Kerry
3 Kima Chemical
6 Lonza Capsugel
9 Microlex e.U
1 Novo Excipients
1 Pharmatrans-Sanaq
2 Pluviaendo
3 Prachin Chemical
1 Qianhao Chemical (Hebei) Co., Ltd
1 Qualicaps
10 Roquette
6 Seppic
4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
9 Sigachi Industries
2 The Dow Chemical Company
3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

44 Coating Systems & Additives, 28 Fillers, Diluents & Binders, 19 Controlled & Modified Release, 14 Disintegrants & Superdisintegrants, 14 Thickeners and Stabilizers, 12 Direct Compression, 10 Granulation, 10 Lubricants & Glidants, 8 Film Formers & Plasticizers, 6 Co-Processed Excipients, 6 Rheology Modifiers, 5 Empty Capsules, 4 Vegetarian Capsules, 4 API Stability Enhancers, 4 Taste Masking, 4 Coloring Agents, 4 Emulsifying Agents, 3 Chewable & Orodispersible Aids, 2 Topical, 1 Surfactant & Foaming Agents, 1 Solubilizers, 1 Parenteral

44 Coating Systems & Additives
28 Fillers, Diluents & Binders
19 Controlled & Modified Release
14 Disintegrants & Superdisintegrants
14 Thickeners and Stabilizers
12 Direct Compression
10 Granulation
10 Lubricants & Glidants
8 Film Formers & Plasticizers
6 Co-Processed Excipients
6 Rheology Modifiers
5 Empty Capsules
4 Vegetarian Capsules
4 API Stability Enhancers
4 Taste Masking
4 Coloring Agents
4 Emulsifying Agents
3 Chewable & Orodispersible Aids
2 Topical
1 Surfactant & Foaming Agents
1 Solubilizers
1 Parenteral

DIGITAL CONTENT

44 NEWS #PharmaBuzz

44 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

4 Regulatory FDF Prices, 5 Annual Reports

4 Regulatory FDF Prices
5 Annual Reports

MARKET PLACE

7 APIs

7 APIs

PATENTS & EXCLUSIVITIES

18 US Patents, 4 Health Canada Patents

18 US Patents
4 Health Canada Patents

$ API Ref.Price (USD/KG) : 654 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

18 All

01 18BRISTOL-MYERS SQUIBB

filter Patent Number Reset all filters

18 All

01 28329159

02 28629171

03 48642025

04 48900566

05 69421192

filter API Patent Reset all filters

18 All

01 14Y

02 4Blank

filter FDF Patent Reset all filters

18 All

01 6Y

02 12Blank

filter Expiration Date Reset all filters

18 All

01 102027-08-08

02 42027-08-11

03 22029-07-24

04 22031-06-13

Product Main Page

01

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

World ADC London

Not Confirmed

BRISTOL-MYERS SQUIBB

World ADC London

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-08

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 8900566

Drug Substance Claim :

Drug Product Claim :

Application Number : 206843

Patent Use Code : U-1725

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

World ADC London

Not Confirmed

BRISTOL-MYERS SQUIBB

World ADC London

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-08

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 8900566

Drug Substance Claim :

Drug Product Claim :

Application Number : 206843

Patent Use Code : U-1725

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

World ADC London

Not Confirmed

BRISTOL-MYERS SQUIBB

World ADC London

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-08

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 8900566

Drug Substance Claim :

Drug Product Claim :

Application Number : 206843

Patent Use Code : U-1724

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

World ADC London

Not Confirmed

BRISTOL-MYERS SQUIBB

World ADC London

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-11

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 8642025

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206843

Patent Use Code : U-1724

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-11

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

World ADC London

Not Confirmed

BRISTOL-MYERS SQUIBB

World ADC London

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-08

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 9421192

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 206843

Patent Use Code : U-1725

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

World ADC London

Not Confirmed

BRISTOL-MYERS SQUIBB

World ADC London

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-08

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 9421192

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 206843

Patent Use Code : U-1724

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

World ADC London

Not Confirmed

BRISTOL-MYERS SQUIBB

World ADC London

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-08

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 9421192

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 206843

Patent Use Code : U-1725

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

World ADC London

Not Confirmed

BRISTOL-MYERS SQUIBB

World ADC London

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-11

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 8642025

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206843

Patent Use Code : U-1724

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-11

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

World ADC London

Not Confirmed

BRISTOL-MYERS SQUIBB

World ADC London

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-06-13

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 8629171

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206843

Patent Use Code : U-1724

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2031-06-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

World ADC London

Not Confirmed

BRISTOL-MYERS SQUIBB

World ADC London

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-06-13

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 8629171

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206843

Patent Use Code : U-1724

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2031-06-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!